HIV-1 AE重组型疫苗构建及免疫原性研究  

Construction and immunogenicity analysis of a vaccine against HIV-1 AE recombinant

作　　者：张聪优[1,2] 万延民[2] 仇超[1] 黄杨[2] 阮力[1] 许雪梅[1] 徐建青[2,1] 

机构地区：[1]中国医学科学院基础医学研究所北京协和医学院基础学院生物物理与结构生物学系,北京100073 [2]复旦大学附属上海市公共卫生临床中心,上海201508

出　　处：《中华疾病控制杂志》2010年第9期831-835,共5页Chinese Journal of Disease Control & Prevention

基　　金：国家“十一五”重大科技专项课题(2008ZX10001-012);国家自然科学基金(30771915)

摘　　要：目的利用AE亚型的膜蛋白,研发抗HI V-1 AE重组型的疫苗并进行免疫原性评价。方法构建表达中国流行株97CNGX2F(HI V-1 AE2F)包膜蛋白gp140的重组痘苗病毒rVVT140AE。使用表达gp140的DNA疫苗和rVVT140AE用初免-加强方式免疫小鼠。免疫结束后第2周处死小鼠,分别检测特异性抗体滴度和特异性T细胞反应。结果本疫苗所活化的特异性抗体滴度在3 200和51 200之间,几何平均值为11 143;总T细胞免疫反应强度为(1 918±442)SFCs/106脾细胞,其中针对env1、env2、env3、env4肽池的免疫反应强度分别为(1 280±330)SFCs/106脾细胞,(66±16)SFCs/106脾细胞,(163±34)SFCs/106脾细胞和(409±96)SFCs/106脾细胞,均显著高于空载体对照组(<10 SFCs/106脾细胞)。结论本实验构建的HI V-1 AE2F株包膜蛋白gp140重组痘苗病毒疫苗可作为针对我国HI V-1流行株的候选疫苗免疫原。Objective To develop an HIV-1 AE recombinant envelope based vaccine since this recombinant has been accounted for high percent of sexual transmitted HIV-1 prevalence.Methods A recombinant Tiantan vaccinia based vaccines rVVT140AE expressing envelope gp140 from a circulating recombinant clade 97CNGX2F（HIV-1 AE2F） was constructed.DNA vaccine expressing gp140 and rVVT140AE was used to immunize mice with a prime/boost strategy.Mice were sacrificed 2 weeks after the final inoculation,then specific antibody titer and T cell responses were measured separately.Results The titers of env-specific antibodies elicited by this vaccines ranged from 3 200 to 51 200,with an geometric average at 11 143.Total T cell responses measured by ELISPOT was（1 918±442） SFCs/106 splenocytes with the responses against four peptide pools env1,env2,env3,env4 at（1 280±330） SFCs/10^6 splenocytes,（66±16） SFCs/10^6 splenocytes,（163±34） SFCs/10^6 splenocytes and（409±96） SFCs/10^6 splenocytes,which were all significantly higher than mock control group（〈10 SFCs/10^6 splenocytes）.Conclusions The HIV-1 AE2F envelope gp140 recombinant vaccinia virus vaccine can be used for HIV-1 strains candidate vaccine immunogen.

关 键 词：HIV疫苗 包膜蛋白 疫苗 合成 

分 类 号：R512.91[医药卫生—内科学] R457.2[医药卫生—临床医学]